retatrutide clinical trials weight loss New Phase 3 data just dropped 👀 Eli Lilly's trial reported average approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats The trillion-dollar peptide. Appearing on

Who may be a good candidate for retatrutide therapy

Medications are for different functions

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

A sample can be 99% pure but 99% pure of the wrong compound

Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, OFarrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z (2022) LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept

Back Laughton, NB, Macallum, AB (1 June 1932) 'The Relation of duodenal mucosa to internal secretion of the pancreas', Proceedings of the Royal Society of London